The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The Current and Future Perspectives of Postbiotics
Open accessAbstract
With the emphasis on intestinal health, probiotics have exploded into a vast market potential. However, new scientific evidence points out that the beneficial health benefits of probiotics are not necessarily directly related to viable bacteria. However, the metabolites or bacterial components of the live bacteria are the driving force behind health promotion. Therefore, scientists gradually noticed that the beneficial effects of probiotics are based on bacteria itself, metabolites, or cell lysates, and these factors are officially named "postbiotics" by the ISAPP. Postbiotic components are diverse and outperform live probiotics in terms of technology, safety, and cost due to their good absorption, metabolism, and organismal distribution. Postbiotics have been shown to have bioactivities such as antimicrobial, antioxidant, anti-inflammatory, anti-proliferative, and immunomodulation. Moreover, numerous studies have revealed the significant potential of postbiotics for disease treatment. This paper first presents the production and classification of postbiotics with examples from lactic acid bacteria (LAB), followed by the mechanisms of action with the most recent pre-clinical and clinical studies and the wide range of non-clinical and clinical applications of postbiotics. Furthermore, the current and future prospects of the postbiotic market with commercial available products are discussed. Finally, we comment on the knowledge gaps and future clinical applications with several examples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
Probiotics and prebiotics in intestinal health and disease: from biology to the clinic
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0173-3 · Cited by 2,059 · cited 1×
“The concept of probiotics has been evolving over the past few decades, with the currently accepted definition describing probiotics as “live microorganisms that can benefit the host when consumed in sufficient quantities [1].”
BackgroundKelly, C. J., Zheng, L., Campbell, E. L., Saeedi, B., Scholz, C. C., Bayless, A. J., Wilson, K. E., Glover, L. E., Kominsky, D. J., Magnuson, A., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.03.005 · Cited by 1,716
Bile acid metabolites control TH17 and Treg cell differentiation
Hang, S., Paik, D., Yao, L., Kim, E., Trinath, J., Lu, J., Ha, S., Nelson, B. N., Kelly, S. P., Wu, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1785-z · Cited by 1,457
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407 · cited 1×
“recently focused on a microbiome-derived metabolite, inosine, that enhances the efficacy of cancer immunotherapy [86].”
BackgroundProbiotics, gut microbiota, and their influence on host health and disease
Sánchez, B., Delgado, S., Blanco‐Míguez, A., Lourenço, A., Gueimonde, M., & Margolles, A. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600240 · Cited by 1,104
Postbiotics: An Evolving Term within the Functional Foods Field
Aguilar-Toalá, J. E., Garcia-Varela, R., Garcia, H. S., Mata-Haro, V., González-Córdova, A. F., Vallejo-Cordoba, B., & Hernández-Mendoza, A. (2018) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2018.03.009 · Cited by 1,078
Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens
Lebeer, S., Vanderleyden, J., & De Keersmaecker, S. C. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2297 · Cited by 1,062
Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis
Song, X., Sun, X., Oh, S. F., Wu, M., Zhang, Y., Zheng, W., Geva-Zatorsky, N., Jupp, R., Mathis, D., Benoist, C., et al. (2020) · Nature · doi:10.1038/s41586-019-1865-0 · Cited by 1,024
Cited by
Che, J., Shi, J., Fang, C., Zeng, X., Wu, Z., Du, Q., Tu, M., & Pan, D. (2024) · Microorganisms · doi:10.3390/microorganisms12040704 · Cited by 52
Machado, P., Ribeiro, F. N., Giublin, F. C. W., Mieres, N. G., Tonin, F. S., Pontarolo, R., Sari, M. H. M., Lazo, R. E. L., & Ferreira, L. M. (2025) · Pharmaceuticals · doi:10.3390/ph18050704 · Cited by 44
Jang, A.-R., Jung, D.-H., Lee, T.-S., Kim, J.-K., Lee, Y.-B., Lee, J.-Y., Kim, S.-Y., Yoo, Y.-C., Ahn, J.-H., Hong, E.-H., et al. (2024) · Nutrition · doi:10.1016/j.nut.2024.112565 · Cited by 20
Wojcieszak-Michalak, M., Kowalska, J., Paraskevopoulou, A., Paraskevopoulos, G., Vávrová, K., Burlaga, N., Różański, J., Misiak, P., Kaczorek, E., & Materna, K. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127293
Metadata
- Authors
- Liang, B., & Xing, D.
- Venue
- Probiotics and Antimicrobial Proteins
- Published
- 2023-02-10
- Volume
- 15
- Issue
- 6
- Pages
- 1626-1643
- ISSN
- 1867-1306 (ISSN-L)
- 1867-1314
- OpenAlex
- W4319826842
- Cited by
- 192
- References
- 32
- FWCI
- 24.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Current and Future Perspectives of Postbiotics. https://app.cochat.ai/papers/10.1007/s12602-023-10045-x
- The paper
- Liang, B., & Xing, D. (2023). The Current and Future Perspectives of Postbiotics. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-023-10045-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.